Boehringer Sues Apotex To Protect Zantac Patent

Law360, New York (February 1, 2008, 12:00 AM EST) -- Boehringer Ingelheim Pharmaceuticals Inc. is suing Apotex Inc., claiming the Canadian company’s generic version of its over-the-counter heartburn treatment Zantac infringes a Boehringer patent.

In a complaint filed Thursday in the U.S. District Court for the District of Delaware, the German drugmaker’s U.S. subsidiary alleges that a recent abbreviated new drug application filed by Apotex with the U.S. Food and Drug Administration infringes a patent held by Boehringer that covers flavor-coated tablets.

The patent, U.S. Patent Number 5,098,715, is used in the manufacturing process of Boehringer’s...
To view the full article, register now.